Symbiotec Pharmalab IPO: Potential 28.85% Listing Gain
By Business Desk
Symbiotec Pharmalab IPO closes Aug 27. Grey Market Premium suggests a 28.85% listing gain, with an estimated listing price of Rs 1,273. Overall subscription stands at 8.2 times.
The Symbiotec Pharmalab IPO is set to close for subscription on August 27, 2026, with its Grey Market Premium (GMP) holding at Rs 285 per share. This indicates an estimated listing price of Rs 1,273, translating to a potential listing premium of 28.85% over the Rs 988 upper price band.
Key IPO Figures
- GMP: Rs 285 per share
- Estimated Listing Price: Rs 1,273
- Potential Listing Premium: 28.85%
- Overall Subscription: 8.2 times by 10:40 a.m. on August 27
- Total Issue Size: Rs 1,757 crore
The public offer, which opened on August 24, consists of a fresh issue of 15 lakh shares worth Rs 150 crore. Additionally, an Offer-For-Sale (OFS) component includes 1.63 crore shares valued at Rs 1,607 crore.
Investor Interest
Non-Institutional Investors (NIIs) have shown significant engagement, subscribing 23.20 times their allocated portion. In contrast, Qualified Institutional Buyers (QIBs) have subscribed 0.61 times.
Symbiotec Pharmalab Ltd., established in 2002, specializes in manufacturing active pharmaceutical ingredients (APIs), nutritional ingredients, and specialty healthcare products. For the fiscal year ending March 31, 2026, the company reported a 15.38% increase in total income and a 13.54% rise in profit after tax (PAT) year-on-year.
Fund Allocation
Proceeds from the fresh issue are designated for the prepayment or repayment of outstanding borrowings and for general corporate purposes. Funds generated from the Offer-For-Sale will be directed to the selling shareholders.
The basis of allotment for the IPO is anticipated to be finalized on August 28, 2026. Shares are tentatively scheduled to list on both the NSE and BSE on September 1, 2026.